Cepham (Somerset, NJ) is taking strategic steps to bridge the gender gap in health research and innovation with a focus on women’s health. The company has outlined a comprehensive plan that includes increased funding for underrepresented areas, inclusive research designs and enhanced communication to raise awareness and support for women’s health initiatives including Women in Nutraceuticals (WIN).
“It typically takes 15-20 years for research discoveries to be adopted into clinical practice. This delay is a significant barrier to implementing new findings in women’s health,” said Anand Swaroop, founder and president of Cepham, and director at large for WIN. “By closing these research gender gaps, we can ensure that women’s health issues receive the attention and resources needed for better health outcomes.”
Swaroop said that immediate policy interventions, driven by insights from successful case studies and a commitment to inclusive research, are essential to fostering a future where women’s health is prioritized and adequately funded.
According to the company, Cepham has been investing in women’s health research since 2013. One of its flagship products, Furocyst, is a proprietary fenugreek seed extract developed to support insulin sensitivity and reduce ovarian cysts. It has been clinically evaluated on 520 patients and shown to improve glucose metabolism and hormonal balance, making it a promising solution for managing polycystic ovary syndrome (PCOS). Furocyst has garnered significant recognition, being supported by five international patents, and the subject of several studies published in peer-reviewed journals.
Additionally, Cepham’s SheVari4, an ayurvedic formulation, addresses menopausal symptoms, including focus and mood, by supporting hormonal balance. By integrating traditional knowledge with modern scientific validation, Cepham has demonstrated the potential for innovative solutions in women’s health.
Cepham emphasizes that while it is committed to addressing women’s health, men’s health remains equally crucial. In the coming months, Cepham will share insights on misconceptions in men’s health research and how the company is working to correct these gaps.
For more information visit https://cepham.com.
